An antibody-drug conjugate (ADC) based on an antibody binding to human AXL and pharmaceutical compositions comprising the ADC for use in the treatment of a cancer comprising administering to a subject a weekly dose of from about 0.45 mg/kg to about 2.0 mg/kg of the ADC once a week for three consecutive weeks followed by a one week resting period without any administration of the ADC so that each cycle time is 28 days including the resting period.
